Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

Aldeyra Therapeutics, Inc. (ALDX) Stock · SELL · CRISIS | LOPJLB

Aldeyra The (ALDX)

Healthcare · Biotechnology · NASDAQ · US

$0.92-3.16%Close

SELLCRISIS · day 12

ALDX▼ SELL

$0.92-3.16%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-09-30

52-week IV0.1%–493.8%

Market cap: $55M
Beta: 1.20
P/E (TTM): -2.37
IV-%ile: 59

IV ATM: 199.0%
Short % float: 6.59%
Days to cover: 3.0
SI change: -3.7%

1W: -21.37%
1M: -36.99%

vs SPY 1W: -22.53%
vs SPY 1M: -39.98%

Industry peers

FMP comparable companies · ranked by market cap

ANROSELLAlto Neuroscience, Inc.$855MCRISISQ 17$24.37+1.41%
CADLSELLCandel Therapeutics, Inc.$728MCRISISQ 19$9.94+2.90%
CTNMSELLContineum Therapeutics, Inc.$503MRECOVERYQ 7$13.38+1.52%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of…

Employees: 6
Headquarters: US
Founded: 2014
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 60.3M
Float: 87.3%

aldeyra.com ↗

Key executives

Todd C. Brady — Chief Executive Officer, President & Director

Michael Alfieri — Head of Finance and Principal Financial & Accounting Officer

Laura Nichols — Operations Manager

SEC filings

EDGAR · CIK 13412350 · ALDX

All filings
10-K
10-Q
8-K
Form 4

Analyst consensus

Buy

Bullish1894.7%

Neutral15.3%

Bearish00.0%

L $7.00Avg $9.67H $12.00

Target$9.67+951.09%

Last$0.92

Company news

benzinga.com · 11d ago

Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally

seekingalpha.com · 11d ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript

marketbeat.com · 11d ago

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease

businesswire.com · 12d ago

Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease

businesswire.com · 12d ago

Aldeyra Therapeutics to Host Regulatory Update Webcast

Market news & ticker search · RSS for ALDX

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE